Neurotez Inc. Awarded Multi-Million Dollar NIH Grant to Advance a …
The News Review:
- Neurotez Inc. Awarded Multi-Million Dollar NIH Grant to Advance a …
- Growing Midwestern Clinical Research rganization Selects mniComm …
- Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
- Blacksburg’s Intrexon: Branching out in biotech
Neurotez Inc. Awarded Multi-Million Dollar NIH Grant to Advance a …
Business Wire (press release)
“The entire Neurotez team is very excited to move our drug forward to the next level. This award shows that translational research – when conducted methodically and by the right people – can be executed most effectively in the environment and culture fostered in small biotech companies” said Nikolaos Tezapsidis founder president & CE of Neurotez Inc. We also strongly believe that this award will effectively serve as a bridge to private capital raises. ” “Leptin treatment has shown striking results in numerous cellular and animal models of AD and reduces all of the major pathological hallmarks associated with the disease and as such markedly improves memory. This award presents a wonderful opportunity to move our impressive preclinical studies into clinical trials in patients” said Mark A.
Related from Fildak: China pledges multi-million-dollar aid to Senegal
Growing Midwestern Clinical Research rganization Selects mniComm …
PR Newswire (press release)
(TCBulletinBoard: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research rganization (CR) has selected mniComm to provide eClinical solutions in connection with two of the CR’s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. “We are pleased to have been selected by this CR to provide eClinical solutions for these important Phase IV studies” said Cornelis F. Wit mniComm’s President and CE.
Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
Business Wire (press release)
Shames Assistant Professor of Surgery Division of Transplant Surgery at the Medical College of Wisconsin “Development of a non-invasive test that could help differentiate between acute renal injury rejection and infection would satisfy a critical unmet need in transplantation. A biomarker test that can accomplish this would be of extreme importance in pre-clinical kidney transplantation research. ” Jim Janicki Vice President and General Manager of Life Technologies’ Transplantation Diagnostics Business “The launch of the PlexMark assay represents the continued expansion of our pre-clinical research business. We are excited about the non-invasive and cost-effective nature of PlexMark and anticipate that research clinicians will want to utilize this product to better understand immunosuppression as it relates to whole kidney function. ” Resources.
Blacksburg’s Intrexon: Branching out in biotech
Roanoke Times
Cory Donovan who directs the NewVa Corridor Technology Council said Intrexon stands out in the high-tech business world locally for several things. It is relatively large as council members and research center tenants go and is one of a small number of NewVa region firms to receive investments from Third Security LLC a Radford venture capital firm. Sunil Chada Intrexon’s senior vice president of clinical research and development said in a news release the firm is “very encouraged” by recent events. Rob Patzig chief investment officer at Third Security said the melanoma therapy is “on track to significantly enhance the safety and efficacy of cancer treatments while also maintaining centralized production and distribution efficiencies. John Kirkwood the physician leading the study could not be reached for comment.
Written by admin on August 3rd, 2009 with
no comments.
Read more articles on News.